Clinical trial
Randomized, Placebo-Controlled, Double-Blind, Phase 2 Study of Gemcitabine-Cisplatin Combined With Two Different Doses of LY293111 or Placebo in Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
NCT00069875 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Randomized, Placebo-Controlled, Double-Blind, Phase 2 Study of Gemcitabine-Cisplatin Combined With Two Different Doses of LY293111 or Placebo in Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
- Lead sponsor
- Eli Lilly and Company
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- September 30, 2003
- Completion date
- December 31, 2005
- Enrollment
- 195
- Sites
- 19
Conditions
As the registry lists them; a condition with its own page is linked.